General Information of Drug (ID: DMK8FHB)

Drug Name
KN-002
Indication
Disease Entry ICD 11 Status REF
Severe asthma CA23 Phase 1 [1]
Drug Type
Small molecule
Cross-matching ID
TTD ID
DI19BZ

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Janus kinase 1 (JAK-1) TT6DM01 JAK1_HUMAN Inhibitor [2]
Janus kinase 2 (JAK-2) TTRMX3V JAK2_HUMAN Inhibitor [2]
Janus kinase 3 (JAK-3) TTT7PJU JAK3_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05006521) Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, PK, and PD of Single Ascending Doses of KN-002 in Healthy Subjects and Multiple Ascending Doses of KN-002 in Subjects With Mild Asthma, Moderate-Severe Asthma and COPD. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Kinaset Therapeutics